News
FDA needs more time to review Tlando to treat testosterone deficiency.- Lipocine Inc.
Lipocine Inc. announced that the FDA has informed the Company that it needs additional time to complete its review of Tlando's New Drug Application ("NDA") and is committed to taking action as expeditiously as possible. The anticipated Prescription Drug User Food Act ("PDUFA") goal date was August 28, 2020 for Tlando.
Although the FDA did not provide a timeline on a new action date, the FDA informed the Company that the review is expected to be completed in the coming weeks. The FDA has not asked for any additional data and the Company has provided the FDA with all information requested to date.
Condition: Testosterone Deficiency
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins